Public Employees Retirement Association of Colorado Sells 3,584 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Public Employees Retirement Association of Colorado decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 10.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,145 shares of the biopharmaceutical company’s stock after selling 3,584 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Amicus Therapeutics were worth $299,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its holdings in shares of Amicus Therapeutics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock worth $780,000 after buying an additional 1,258 shares in the last quarter. American International Group Inc. increased its holdings in Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 1,298 shares in the last quarter. Arizona State Retirement System raised its position in Amicus Therapeutics by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Amicus Therapeutics by 1.1% in the second quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 2,737 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Amicus Therapeutics by 6.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,471 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 2,918 shares during the last quarter.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The disclosure for this sale can be found here. Insiders have sold 21,100 shares of company stock worth $226,375 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $10.71 on Friday. The firm has a fifty day moving average of $11.07 and a two-hundred day moving average of $10.68. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -21.86 and a beta of 0.69. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The firm’s revenue was up 34.0% on a year-over-year basis. As a group, equities research analysts predict that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on FOLD. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a report on Friday, September 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. JPMorgan Chase & Co. lowered their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.